SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
January 31, 2013
Omni Bio Pharmaceutical, Inc.
(Exact name of registrant as specified in its charter)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
The information set forth in Item 5.02 below relating to the warrant issued to Michael E. Kamarck is incorporated by reference into this Item 3.02.
On January 31, 2013, the Board of Directors (the “Board”) of Omni Bio Pharmaceutical, Inc. (the “Company”) appointed Michael E. Kamarck, age 61, as a director of the Company. In connection with his appointment, Dr. Kamarck was granted a warrant to purchase 250,000 shares of the Company’s common stock at an exercise price of $0.30 per share. The warrant vested immediately and has a seven year life. The Company issued the warrant pursuant to Section 4(2) of the Securities Act of 1933, as amended.
From 2010 to 2012, Dr. Kamarck was employed by Merck as President of Merck BioVentures and Senior Vice President of Vaccines and Biologics Manufacturing. From 2001 to 2009, he was employed by Wyeth, where he held various senior executive positions, including President, Technical Operations and Product Supply and was responsible for global technical operations for all of the Wyeth businesses. Dr. Kamarck also served as a member of the Wyeth Management Committee. Prior to Wyeth, he was employed by Bayer AG for 17 years in a variety of technical and leadership capacities.
On February 6, 2013, the Company issued a press release announcing the appointment of Dr. Kamarck to the Board. A copy of the press release is furnished herewith as Exhibit 99.1.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.